Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients

AIDS Patient Care and STDs

Volumn 25, Issue 9, 2011, Pages 509-515

  Wang, Xiaodong ^a   Boffito, Marta ^b   Zhang, Jenny ^a   Chung, Ellen ^a   Zhu, Li ^a   Wu, Yaoshi ^a   Patterson, Kristine ^c   Kashuba, Angela ^c   Tebas, Pablo ^d   Child, Michael ^a   Mahnke, Lisa ^a   Bertz, Richard ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b St Stephen's Health Centre   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; FAMOTIDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DRUG DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; OLIGOPEPTIDE; PHOSPHONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; SIDE EFFECT; VIRUS LOAD; COHORT ANALYSIS; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; METABOLISM; MIDDLE AGED;

ADENINE; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FAMOTIDINE; FEMALE; HISTAMINE H2 ANTAGONISTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PYRIDINES; RITONAVIR; VIRAL LOAD;

EID: 80051998401     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0113     Document Type: Article

References (20)

1. Swainston HT, Scott LJ. Atazanavir: A review of its use in the management of HIV infection. Drugs 2005;65:2309-2336. (Pubitemid 41573606)
2. Reyataz (atazanavir). [US prescribing information] Princeton, NJ: Bristol-Myers Squibb, 2010.
3. Perez-Elias MJ. Atazanavir: Simplicity and convenience in different scenarios. Expert Opin Pharmacother 2007;8: 689-700. (Pubitemid 46547021)
4. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718. (Pubitemid 43884298)
5. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Oncedaily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1- infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-655.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. Department of Health and Human Services. www.aidsinfo .nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Last accessed December 10, 2010).
7. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21: 1431-1438. (Pubitemid 26066634)
8. Luber A, Garg V, Gharakhanian S, Team VHP. Survey of medication used by HIV-infected patients that affect gastrointestinal acidity and potential for negative drug interactions with HAART [Abstract 206]. Presented at: 7th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland: November 14-18, 2004.
9. Luber AD. Use of acid-reducing agents in protease inhibitorbased HAART and the potential for negative treatment outcomes. AIDS Read 2005;15:692-700.
10. Beique L, Giguere P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: A systematic review. HIV Med 2007;8:335-345. (Pubitemid 47163265)
11. Falcon RW, Kakuda TN. Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 2008;47:75-89.
12. Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and the effects on protease inhibitors. Ann Pharmacother 2006;40:1974-1983. (Pubitemid 44747467)
13. Eley T, Agarwala S, Wang R, et al. Analysis of intra-gastric pH and atazanavir bioavailability in healthy subjects. Presented at: 7th Workshop on Clinical Pharmacology in HIV Therapy [Abstract 40]. Lisbon, Portugal: April 20-22 2006.
14. Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects [Abstract 11]. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada: April 28-30, 2005.
15. Agarwala S, Perssson A, Eley T, et al. Effect of famotidine 20 and 40mg dosing regimens on the bioavailability of atazanavir with ritonavir in combination with tenofovir in healthy subjects [Abstract 568]. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA: February 25-28, 2007.
16. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008;3:296-305. (Pubitemid 351521014)
17. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48:2091-2096. (Pubitemid 38691603)
18. Agarwala S, Eley T, Villegas C, Wang Y, Hughes E, Grasela D. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects [Poster 2.9]. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Canada: April 28-30, 2005.
19. Zhu L, Liao S,Child M, et al.CASTLE study: pharmacokinetics and inhibitory quotient of atazanavir/ritonavir 300/100mg once daily compared to lopinavir/ritonavir 400/100mg twice daily, each in combination with fixed dose tenofoviremtricitabine oncedaily, are supportive of 48week efficacy and safety in HIV-1 infected, treatment-naïve subjects [Poster 023]. Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy. New Orleans, LA: April 7-9, 2008.
20. Reyataz. Summary of product characteristics. Uxbridge, UK: Bristol-Myers Squibb, 2010.